Spotlight on panitumumab in metastatic colorectal cancer

BioDrugs

Volumn 24, Issue 4, 2010, Pages 275-278

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Colorectal cancer

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; INJECTION SITE HYPERSENSITIVITY; METASTASIS; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; COLORECTAL NEOPLASMS; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 77954598377     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11205460-000000000-00000     Document Type: Review

References (28)

1. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 2010; 70 (8): 1059-1078
2. Foon KA, Yang X-D, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004 Mar 1; 58 (3): 984-990
3. Amgen Inc. Vectibix® (panitumumab) solution for intravenous infusion: US prescribing information [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/125147s080lbl.pdf [Accessed 2010 Jan 14]
4. Foltz IN,King CT, Liang M, et al. Panitumumab induces internalization of the epidermal growth factor receptor (EGFr) [abstract no. B43]. 17th AACRNCI EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA)
5. Giannopoulou E, Antonacopoulou A, Matsouka P, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 2009 Dec; 29 (12): 5077-5082
6. Yang X-D, Jia X-C, Corvalan JRF, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999Mar 15; 59 (6): 1236-1243
7. Lynch DH, Yang X-D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002 Feb; 29 (1 Suppl. 4): 47-50
8. Freeman D, McDorman K, Bush T, et al. Mono- and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT- 29 colon carcinoma xenografts: correlation with pharmacodynamic parameters [abstract no. 313]. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2004 Sep 28-Oct 1; Geneva
9. Ma P, Yang B-B, Wang Y-M, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 2009 Oct; 49 (10): 1142-1156
10. Siena S, Cassidy J, Tabernero J, et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared toFOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial [abstract no. 283]. 2010 Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando (FL)
11. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009 Feb 10; 27 (5): 672-680
12. Peeters M, Price TJ, Hotko YS, et al. Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO) [abstract no. 282]. 2010 Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando (FL)
13. Peeters M, Price T, Hotko Y, et al. Randomized phase 3 study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patientswith metastatic colorectal cancer (mCRC) [abstract no. 14LBA]. 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology; 2009 Sep 20-24; Berlin
14. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007 May 1; 25 (13): 1658-1664
15. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008 Apr 1; 26 (10): 1626-1634
16. Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010 Apr 1; 16 (7): 2205-2213
17. Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2009 May; 39 (5): 321-326
18. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007 Sep 1; 110 (5): 980-988 (Pubitemid 47312862)
19. Amado RG, Wolf M, Freeman D, et al. Association of KRAS mutational status and efficacy of panitumumab monotherapy for the treatment (TX) of metastatic colorectal cancer (MCRC): results of pooled data from 4 clinical studies [abstract no. 359P]. 33rd Congress of the European Society for Medical Oncology; 2008 Sep 12-16; Stockholm
20. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005 May; 6 (5): 279-286
21. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007 Aug 1; 25 (22): 3238-3245
22. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008 Dec 10; 26 (35): 5705-5712
23. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009 Mar 1; 69 (5): 1851-1857
24. CarcerenyE,Castellvi-Bel S, Alonso V, et al.EGFRpolymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab [abstract no. 4124]. 44th AnnualMeeting of the American Society of Clinical Oncology; 2008May 30-Jun 2; Chicago (IL)
25. Perkins G, Lièvre A, Ramacci C, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti- EGFR antibodies in colorectal cancer. Int J Cancer. Epub 2010 Jan 4
26. Siena S, Sartore-Bianchi A, Di Nicolantonio F. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009 Oct 7; 101 (19): 1308-1324
27. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010 Mar 10; 28 (8): 1351-1357
28. Starcevic M, Weeraratne D, Lofgren JA, et al. Panitumumab immunogenicity in two phase III trials of patients with metastatic colorectal cancer (mCRC) treated with panitumumab plus FOLFIRI or FOLFOX4 [abstract no. 433]. 2010 Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando (FL)